Medicare and Weight-Loss Medications: A Pharmacist's FAQ on the GLP-1 Bridge Program

This FAQ was fact-checked by Mohammed Chammout, PharmD, BCMTMS.

For years, Medicare beneficiaries seeking glucagon-like peptide (GLP)-1 medications for weight loss have hit the same wall at the pharmacy counter: no coverage, and monthly costs upward of $500. That changed on July 1, 2026, when the Centers for Medicare & Medicaid Services (CMS) launched Medicare GLP-1 Bridge, a nationwide demonstration program offering eligible Part D beneficiaries access to select weight-loss medications for a flat $50 monthly copay.

The Bridge is not a simple coverage expansion. It is a separate claims pathway with its own rules, and both patients and pharmacy teams will need to understand how it works as it goes live.

Q1: What is the Medicare GLP-1 Bridge program?

The Bridge is a short-term demonstration program established under Section 402 demonstration authority. It runs from July 1, 2026, through December 31, 2027, and was originally designed to serve as a transition to the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) program, which had been scheduled to launch for Medicare Part D plan sponsors in January 2027. In April 2026, CMS delayed the Part D portion of BALANCE indefinitely, citing insurer feedback, and extended the Bridge through December 31, 2027, to cover the gap.

Importantly, the Bridge does not operate through a beneficiary's existing Part D plan or pharmacy benefit manager. CMS has set up a central processor that independently handles prior authorizations, claims adjudication, and pharmacy payments for all Bridge prescriptions. Part D sponsors are not involved and carry no financial risk for these claims.

Q2: Which medications are covered under the Bridge?

The Bridge covers a specific list of formulations:

• Wegovy (semaglutide; Novo Nordisk): injectable and tablet formulations
• Zepbound (tirzepatide; Eli Lilly): KwikPen formulation only
• Foundayo (Eli Lilly): all formulations

Zepbound single-dose vials and single-dose pens are not eligible under the program. GLP-1s prescribed for type 2 diabetes, cardiovascular risk reduction, sleep apnea, or metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis.—such as Ozempic (semaglutide; Novo Nordisk) and Mounjaro (tirzepatide; Eli Lilly)—remain under standard Part D coverage and fall outside the Bridge entirely.

Q3: Who qualifies for the Bridge program?

Eligibility hinges on the clinical picture at the time a patient started GLP-1 therapy, not their status when the Bridge claim is submitted. A patient who began treatment with a body mass index (BMI) of 37 and has since lost weight to a BMI of 31 may still qualify, as long as the prescriber attests that the BMI threshold was met at initiation.

To participate, patients must be enrolled in a standalone Part D prescription drug plan or a Medicare Advantage plan with drug coverage, and meet one of the following clinical criteria:

• BMI of 35 or higher;
• BMI of 30 or higher plus at least 1 of the following: heart failure with preserved ejection fraction, uncontrolled hypertension despite treatment, or chronic kidney disease (stage 3a or above);
• or BMI of 27 or higher plus at least 1 of the following: prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.

Patients enrolled in private fee-for-service plans, Programs of All-Inclusive Care for the Elderly organizations, or fallback plans are not eligible.

Q4: How does a Bridge claim actually get processed at the pharmacy?

This is where pharmacy teams need to pay close attention. CMS has assigned a dedicated Bank Identification Number (BIN 028918) and Processor Control Number (PCN MEDDGLP1BR) exclusively for Bridge claims. These route to the central processor—not to the patient's Part D plan. Submitting a Bridge claim through standard Part D processing will result in a rejection.

Prior authorizations also go directly to the central processor rather than the Part D plan, which is a new workflow for many prescriber offices. Pharmacists should expect to field questions from providers unfamiliar with the process in the weeks following launch.

On the payment side, pharmacies collect the $50 copay directly from the beneficiary and are reimbursed by the central processor at no less than wholesale acquisition cost minus the copay, plus a dispensing fee and applicable sales tax. No opt-in is required, as all pharmacies participate automatically.

Q5: What do pharmacists need to know to counsel patients accurately?

A few points are especially important for pharmacist counseling:

• The Bridge is not a Part D benefit. Patients already receiving a covered GLP-1 for diabetes, cardiovascular risk, sleep apnea, or MASH stay on their existing Part D coverage and are not eligible for the Bridge. Their workflow doesn't change.
• The $50 copay doesn't count toward the Part D out-of-pocket cap. Because the Bridge operates outside standard Part D, the copay does not apply toward the $2100 annual out-of-pocket maximum in 2026.
• Formulation matters. A patient assuming any Zepbound product qualifies may be surprised to learn the single-dose vial and pen are excluded—only the KwikPen formulation is covered.

Pharmacists are also likely to be the first point of contact when a claim is rejected due to a prior authorization sent to the wrong processor, making front-line knowledge of the BIN/PCN routing essential.

Q6: Is there anything low-income patients should watch for?

Yes, and it is a detail that can catch both patients and pharmacy staff off guard. For beneficiaries enrolled in the Low-Income Subsidy (LIS) program, LIS cost-sharing subsidies do not apply to Bridge claims. A patient who is accustomed to paying little or nothing for medications under LIS will owe the full $50 Bridge copay.

Pharmacists should compare a patient's standard plan cost-sharing for the drug against the $50 Bridge copay before dispensing, particularly for LIS beneficiaries. In most cases, existing plans do not cover GLP-1s for weight loss at all, so the Bridge will still be the more affordable path—but that comparison is worth confirming rather than assuming.

The Bottom Line

The Medicare GLP-1 Bridge program represents the most significant expansion of weight loss drug access for Medicare beneficiaries to date. Because it operates through a separate claims pathway with its own processor, eligibility rules, and cost-sharing structure, pharmacists who understand the mechanics will be best positioned to guide patients—and prescribers—through a program many have been waiting years to see.